1Ludwig H,Khayat D,Giaccone G,et al.Proteasome inhibitionand its clinical prospects in the treatment of hematologic andsolid malignancies[].Cancer.2005
2Reeder C B,Reece D E,Kukreti V,et al.Cyclophosphamide,bortezomib and dexamethasone induction for newly diagnosedmultiple myeloma:high response rates in a phaseⅡclinical tri-al[].Leukemia.2009
3Chanan-Khan AA,Kaufman JL,Mehta J,et al.Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure:a multicenter retrospective study[].Blood.2007
4Jackson G,Einsele H,Moreau P,et al.Bortezomib,a novelproteasomes inhibitor,in the treatment of hematologic maligna-ncies[].Cancer Treatment Reviews.2005
5Mateos MV,Hernandez JM,Hernandez MT,et al.Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study[].Blood.2006
6Richardson PG,Sonneveld P,Schuster MW,et al.Bortezomib or high-dose dexamethasone for relapsed multiple myeloma[].New England Journal of Homeopathy.2005
4Moore H, Romeril K. Multiple myeloma presenting with a fever of un- known origin and development of thrombotic thrombocytopenic purpura post- bortezomib[J].InternMed J, 2011,41 (4) : 348 - 350.
